Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626795 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 773
- Enrollment target
NCT00626795 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 773 participants.
The verdict
NCT00626795, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 773 participants
- Enrollment target
Study Summary
An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner according to age groups starting with the oldest age group.
Interventions
- DRUG TD1414 2% cream
- DRUG Bactroban® (mupirocin) 2% cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 773 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626795
The ClinicalTrials.gov registry entry for NCT00626795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 773 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TD1414 2% cream is the first listed.
NCT00626795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626795 about?
NCT00626795 is a clinical study titled "Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)". An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children ...
What is the current status of trial NCT00626795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 773 participants. The study started on 2008-02. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00626795?
The interventions under investigation include: TD1414 2% cream (DRUG), Bactroban® (mupirocin) 2% cream (DRUG).
Who is sponsoring clinical trial NCT00626795?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.